SLE患者血清DNase-I蛋白水平与酶活性失衡:与线粒体DNA及低密度粒细胞的关系
该研究在144例SLE患者和42例对照中分析DNase-I及其调控因子与循环DNA降解及低密度粒细胞亚群的关系,发现SLE患者DNase-I蛋白水平升高但酶活性未相应增加,抗DNase-I抗体升高和血浆凝溶胶蛋白降低可能共同参与该失衡,mtDNA在对照中呈稳态调节作用而在SLE中被破坏。
要点
- SLE患者血清DNase-I蛋白水平升高但酶活性未相应增加,抗dsDNA阳性者循环DNA浓度最高。
- 抗DNase-I抗体在SLE患者中升高并与DNase-I/cirDNA比值正相关。
- 血浆凝溶胶蛋白在活动期或合并心血管病患者中降低,较高水平与较少CD16neg-LDG相关。
核心结论
- SLE中DNase-I蛋白水平与酶活性失衡可能受抗DNase-I抗体升高和血浆凝溶胶蛋白降低影响,共同损害循环DNA降解并促进抗DNA自身抗体产生。
- mtDNA在对照中与循环DNase-I水平及活性相关,提示稳态调节作用,而该作用在SLE中被破坏。
- 血浆凝溶胶蛋白可能通过维持DNase-I活性和限制CD16neg-LDG扩增发挥保护作用,提示其在SLE相关心血管并发症中的潜在治疗应用。
研究设计与样本
- 在SLE患者(n=144)和对照(n=42)中,用免疫分析法量化DNase-I、抗DNase-I抗体和血浆凝溶胶蛋白水平。
- 用荧光法测定DNase-I活性和循环DNA浓度,用qPCR量化线粒体/核DNA,用流式细胞术检测低密度粒细胞。
主要发现
- SLE患者血清DNase-I水平升高但DNase活性未相应增加,抗dsDNA阳性患者中尤为明显且循环DNA浓度最高。
- 抗DNase-I抗体水平在SLE患者中升高,并与DNase-I/cirDNA比值正相关。
- 血浆凝溶胶蛋白水平在活动期患者或合并心血管病患者中降低,较高水平与较少CD16neg-LDG相关。
- mtDNA可能促进CD16pos-LDG生成,后者在SLE中增加并与DNase活性负相关。
- 对照中mtDNA与循环DNase-I水平及活性相关,提示稳态作用。
临床怎么用
- SLE中DNase-I蛋白水平与酶活性失衡及抗DNase-I抗体和血浆凝溶胶蛋白变化可能参与循环DNA降解受损。
- 血浆凝溶胶蛋白水平降低与活动期或心血管病相关,较高水平与较少CD16neg-LDG相关。
- 血浆凝溶胶蛋白对DNase-I活性的保护及限制CD16neg-LDG扩增的作用提示其潜在治疗应用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the role of DNase-I and its main regulatory factors controlling the cirDNA degradation, in relation to LDG subsets in SLE. METHODS: DNase-I, anti-DNase-I antibodies and plasma gelsolin (pGSN) levels were quantified using immunoassays in SLE patients (n = 144) and controls (n = 42). DNase-I activity and cirDNA concentrations were determined by fluorescence-based assays, while mitochondrial/nuclear DNA (mtDNA/nDNA) was quantified by qPCR and LDGs by flow cytometry. RESULTS: Serum DNase-I levels were increased in SLE without a concomitant increase in DNase activity, particularly among anti-dsDNApositive patients, who also displayed the highest cirDNA concentrations. Furthermore, anti-DNase-I antibody levels were elevated in these patients and positively correlated with the DNase-I/cirDNA ratio. Upregulation of DNase-I was counteracted by the DNase-regulatory protein pGSN, whose levels were reduced in active patients or with cardiovascular disease. Moreover, higher pGSN levels were associated with fewer CD16neg-LDG, an atherogenic subset. Notably, mtDNA may contribute to the generation of CD16pos-LDG, which were increased in SLE and inversely associated with DNase activity. However, mtDNA in controls correlated with circulating DNase-I levels and activity, suggesting a homeostatic role. CONCLUSION: The DNase-I levels vs enzymatic activity imbalance in SLE may be influenced by elevated anti-DNase-I antibodies and diminished pGSN concentrations, collectively impairing cirDNA degradation and promoting anti-DNA autoantibody production. Additionally, our findings suggest a homeostatic role for mtDNA in DNase-I regulation, which is disrupted in SLE. Moreover, pGSN appears to exert a protective effect by preserving DNase-I activity and restraining the CD16neg-LDGs expansion, highlighting its potential therapeutic application in SLE-related cardiovascular complications.
引用
- Tobío-Parada U, Rodríguez-Carrio J, Martínez-Zapico A, et al. Imbalance between serum DNase-I protein levels and enzymatic activity in SLE: link with mitochondrial-DNA and low-density granulocytes. Rheumatology (Oxford). 2026. PMID: 41183111. doi:10.1093/rheumatology/keaf584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。